| (Values in U.S. Thousands) | Jun, 2021 | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,580 | -14,030 | -360 | -190 | -240 |
| Net Income Growth | +74.48% | -3,797.22% | -89.47% | +20.83% | -84.62% |
Boston Therapeutics (BTHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Boston Therapeutics, Inc. is a pharmaceutical company engaged in the development, manufacturing, and commercialization of compounds for the treatment of diabetes and inflammatory diseases. The Company focuses on glyco-pathology. Its product portfolio includes SUGARDOWN(R), PAZ320 and IPOXYN(TM). Boston Therapeutics, Inc. is based in Manchester, New Hampshire.